{"organizations": [], "uuid": "bb29fad50e8e8386df652dc7f8f3a2917191f62e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180329.html", "section_title": "Archive News &amp; Video for Thursday, 29 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ovid-therapeutics-reports-q4-loss/brief-ovid-therapeutics-reports-q4-loss-per-share-0-45-idUSASC09UA9", "country": "US", "domain_rank": 408, "title": "Ovid Therapeutics Reports Q4 Loss Per Share $0.45", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.766, "site_type": "news", "published": "2018-03-30T04:29:00.000+03:00", "replies_count": 0, "uuid": "bb29fad50e8e8386df652dc7f8f3a2917191f62e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ovid-therapeutics-reports-q4-loss/brief-ovid-therapeutics-reports-q4-loss-per-share-0-45-idUSASC09UA9", "ord_in_thread": 0, "title": "Ovid Therapeutics Reports Q4 Loss Per Share $0.45", "locations": [], "entities": {"persons": [], "locations": [{"name": "ovid", "sentiment": "none"}], "organizations": [{"name": "ovid therapeutics inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 29 (Reuters) - Ovid Therapeutics Inc:\n* OVID THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE PROGRESS\n* Q4 LOSS PER SHARE $0.45 * Q4 EARNINGS PER SHARE VIEW $-0.41 â€” THOMSON REUTERS I/B/E/S\n* OVID THERAPEUTICS - PLAN TO INITIATE PHASE 2 CLINICAL TRIAL WITH OV101 FOR TREATMENT OF ADOLESCENTS AND YOUNG ADULTS WITH FRAGILE X SYNDROME IN 2018\n* TOPLINE DATA FOR PHASE 1B/2A CLINICAL TRIAL OF TAK-935/OV935 EXPECTED IN SECOND HALF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-30T04:29:00.000+03:00", "crawled": "2018-03-30T12:48:10.005+03:00", "highlightTitle": ""}